Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
15 December 2021 | Story Xolisa Mnukwa | Photo Supplied
Former UFS 2020/2021 Student Representative Council (SRC) member, Michael Mnguni describes the journey he travelled towards obtaining his BA in Governance and Political Transformation in 2021.

“I have travelled a long journey, from receiving my acceptance letter back in February 2017 after applying late, to obtaining a BA in Governance and Political Transformation in 2021. 

“I am the child of a single mother who worked as a domestic worker and resigned after I obtained my qualification. Her employer provided us with R10 000 to travel to Bloemfontein in 2017 – a day before registration was supposed to close – to pay for registration, which was about R6 000 at that time.” 

This is how UFS and former Student Representative Council (SRC) member, Michael Mgnuni, describes his journey from destitute student to SRC member and eventually UFS graduate.  

Mguni, who served on the 2020/2021 Bloemfontein Campus SRC responsible for the portfolio: Associations Student Council, said the hardships he faced instilled a desire for continuous improvement. 

“I did not have any form of funding, and back home no one thought I would make it to university because I did not get admitted to other institutions. I am a first-generation student and the firstborn in my family. The past five years have not been easy; especially when you are living far from home, you have to be independent and aware of what is happening in your surroundings.”

On 10 December 2021, Mgnuni became one of the hundreds of graduates who received their qualifications during the UFS virtual graduation ceremonies, obtaining a Bachelor of Arts in Governance and Political Transformation. 

“To obtain this qualification, I would go many days without food and study on an empty stomach. I was dealing with my own mental-health issues while attending to the well-being of others around me, because they became my brothers and sisters.” 

“My graduation journey was not easy; for the first four months at varsity, I travelled from Phahameng to school – living in my aunt’s back room. I had no funding, but my mother would send me money from the little she had, to ensure that I didn’t go to bed on an empty stomach. Through it all, I have conquered. My experiences inspired me to become a student activist, because I didn’t want prospective and returning UFS students to experience the same struggles I went through.” 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept